Rheumatology
1051 – 1060 of 1579
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
EULAR points to consider for conducting clinical trials in systemic lupus erythematosus
(
- Contribution to journal › Article
-
Mark
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas:relative risks and time-trends in the Swedish Biologics Register
(
- Contribution to journal › Article
-
Mark
Renal function is mostly preserved in patients with systemic sclerosis.
(
- Contribution to journal › Article
-
Mark
Functional bowel symptoms and GnRH antibodies: common findings in patients with primary Sjogren's syndrome but not in systemic sclerosis.
(
- Contribution to journal › Article
-
Mark
Six and 12 Weeks Treatment Response Predicts Continuation of Tumor Necrosis Factor Blockade in Rheumatoid Arthritis: An Observational Cohort Study from Southern Sweden.
(
- Contribution to journal › Article
-
Mark
Mitochondrial DNA polymorphisms are associated with susceptibility and phenotype of systemic lupus erythematosus.
(
- Contribution to journal › Article
-
Mark
Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation.
(
- Contribution to journal › Article
-
Mark
A longitudinal follow-up of hand involvement and activities of daily living in early systemic sclerosis.
(
- Contribution to journal › Article
-
Mark
Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells.
(
- Contribution to journal › Article
-
Mark
Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register.
(
- Contribution to journal › Article